Clinical trial
Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Combination With Rituximab, in Japanese Patients With Waldenstrom's Macroglobulinemia (WM)
NCT04062448 is registered in ClinicalTrials.gov with Janssen Pharmaceutical K.K. as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- Phase 2 Study of Bruton's Tyrosine Kinase (BTK) Inhibitor, Ibrutinib (PCI-32765) in Combination With Rituximab, in Japanese Patients With Waldenstrom's Macroglobulinemia (WM)
- Lead sponsor
- Janssen Pharmaceutical K.K.
- Phase
- Phase 2
- Overall status
- Completed
- Start date
- September 25, 2019
- Completion date
- March 2, 2023
- Enrollment
- 16 (actual)
- Sites
- 9
Conditions
As the registry lists them; a condition with its own page is linked.